BioAge Labs (BIOA) vs Rocket Pharmaceuticals (RCKT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
BioAge Labs (BIOA) has outperformed Rocket Pharmaceuticals (RCKT) over the past year, gaining 9.5% versus a loss of 22.4%. Rocket Pharmaceuticals is the larger company by market cap ($288.7 million vs $285.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIOA | RCKT |
|---|---|---|
| Share price | $6.21 | $2.63 |
| Market cap | $285.02M | $288.71M |
| 1-day change | -0.80% | +3.75% |
| YTD return | -53.06% | -25.07% |
| 1-year return | +9.52% | -22.42% |
| 5-year return | — | -90.58% |
| EPS (TTM) | $-2.39 | $-0.17 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $25.96 | $5.45 |
| 52-week low | $5.04 | $2.42 |
| Distance from 52-week high | -76.07% | -51.74% |
| Analyst consensus | none | buy |
| Avg. price target upside | +473.75% | +223.19% |
| Average volume | 918.75K | 1.67M |
| Shares outstanding | 45.90M | 109.77M |
| Employees | 60 | 202 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BIOA has outperformed RCKT by 31.9 percentage points over the past year.
About BioAge Labs
BIOA stock →BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging.
Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees
About Rocket Pharmaceuticals
RCKT stock →Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage.
Health Care · Biotechnology: Pharmaceutical Preparations · 202 employees
BIOA vs RCKT FAQ
Which is bigger, BioAge Labs or Rocket Pharmaceuticals?
Rocket Pharmaceuticals (RCKT) is larger, with a market capitalization of $288.71M compared with $285.02M for BioAge Labs (BIOA).
Which stock has performed better over the past year, BIOA or RCKT?
BIOA returned +9.52% over the past 12 months, compared with -22.42% for RCKT (price return, excluding dividends). Past performance does not predict future results.
Are BioAge Labs and Rocket Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.